NICE does not recommend Kisplyx (lenvatinib) from Eisai and Fotivda (tivozanib) from EUSA as treatments for renal cell carcinoma.

The National Institute for Health and Care Excellence (NICE) is not recommending Kisplyx (lenvatinib) from Eisai in combination with everolimus for previously treated patients with renal cell carcinoma because of uncertainties in the clinical evidence. While trial data suggest that the combination boosts the length of time people live by 10.1 months versus everolimus alone, results were unreliable because the main trial included just a small number of patients. Compared to comparator therapies, cost-effectiveness estimates for Kisplyx plus everolimus “were much more” than what is normally considered value for money - £30,000 per quality-adjusted life year gained.

NICE has also rejected Fotivda (tivozanib) from EUSA as a treatment for people who have advanced renal cell cancer and have not yet received any treatment. According to the appraisal committee, the evidence on whether the drug increases the overall length of time people live is “very uncertain”.“At best, Fotivda may have a similar effect as current treatments available on the NHS, sunitinib or pazopanib, but it may not be as good therefore it is not recommended.